Therefore, TM4SF5 in hepatocytes may modulate homoeostatic blood glucose levels as shown in this study, although hepatic TM4SF5 also play roles in the development of pathological phenotypes for non‐alcoholic fatty liver disease (Lee et al., 2022; Ryu et al., 2021) and hepatocellular carcinoma (Lee et al., 2008; Sun et al., 2021). The gene discussed is TM4SF5; the disease is metabolic dysfunction-associated steatotic liver disease.